A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer, Lung Cancer

In brief

This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations

Key facts

Study ID
NCT06644768
Run by
Daiichi Sankyo
People needed
137
Starts
2024-10-30
Expected to finish
2030-04-30
Last updated by the study team
2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.